Page last updated: 2024-12-11

n-iodoallyl-2-carbomethoxy-3-(4-fluorophenyl)tropane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-iodoallyl-2-carbomethoxy-3-(4-fluorophenyl)tropane: a SPECT imaging agent for viewing dopamine transporter sites; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6440180
CHEMBL ID4301492
CHEBI ID135696
SCHEMBL ID1650069
MeSH IDM0267876

Synonyms (20)

Synonym
altropane
CHEBI:135696
8-azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-(3-iodo-2-propenyl)-, methyl ester, (1r-(1alpha,2alpha,3alpha,5alpha,8(e)))-
unii-1q4092099o
8-azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-((2e)-3-iodo-2-propenyl)-, methyl ester, (1r,2s,3s,5s)-
180468-34-2
1q4092099o ,
2beta-carbomethoxy-3beta-(4-fluorophenyl)-n-(3-iodo-e-allyl)nortropane
iacft
n-iodoallyl-2-carbomethoxy-3-(4-fluorophenyl)tropane
8-azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-(3-iodo-2-propenyl)-, methyl ester, (1r-(1.alpha.,2.alpha.,3.alpha.,5.alpha.,8(e)))-
8-azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-((2e)-3-iodo-2-propen-1-yl)-, methyl ester, (1r,2s,3s,5s)-
iacft [mi]
DB04947
SCHEMBL1650069
Q4737006
methyl (1r,2s,3s,5s)-3-(4-fluorophenyl)-8-[(e)-3-iodoprop-2-enyl]-8-azabicyclo[3.2.1]octane-2-carboxylate
CHEMBL4301492
DTXSID901027571
AKOS040750366

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"These results confirm the study hypothesis that central dopamine transporter occupancy parallels peripheral pharmacokinetic findings in orally administered long-acting dexmethylphenidate in later hours after administration."( Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane.
Bonab, AA; Clarke, A; Dougherty, DD; Fischman, AJ; Martin, J; Mirto, T; Spencer, TJ, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
azabicycloalkane
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (25.00)18.2507
2000's9 (37.50)29.6817
2010's9 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.09 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (20.00%)5.53%
Reviews3 (12.00%)6.00%
Case Studies1 (4.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (64.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]